Described are extended release drug-loaded microparticles, pharmaceutical compositions comprising them, methods of making them, and therapeutic methods using them.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p.ex. phénytoïne
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present disclosure provides methods of detection and diagnosis of ectopic endometriosis. The disclosure further provides compositions, medicaments and methods for treating or preventing ectopic endometriosis.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 31/473 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. acridines, phénantridines
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention also provides new bacteriophage strains.
The present disclosure relates to methods for preparing peptide salts, in particular pharmaceutically acceptable peptide salts, such as salts of atosiban (e.g. atosiban pamoate). The present disclosure further extends to the preparation of particles of such salts, such as via a spray drying process.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and biopharmaceutical products, preparations and agents; pharmaceutical and biopharmaceutical products, preparations and agents used for the treatment of diseases and conditions in the area orthopaedics
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and biopharmaceutical products, preparations and agents; pharmaceutical and biopharmaceutical products, preparations and agents used for the treatment of diseases and conditions in the area orthopaedics
9.
METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Disclosed herein are small molecule follicle-stimulating hormone (FSH) receptor modulators, methods of making them, and therapeutic methods using them.
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; dietetic food and substances
adapted for medical use; dietary supplements for humans;
medical preparations. Surgical and medical apparatus and instruments. Education; arranging, organizing and conducting of
educational and scientific events and forums; publication of
printed matter, including in electronic form (other than for
advertising purposes). Medical services; human healthcare services; medical
information services.
13.
STEREOSELECTIVE SYNTHESIS OF INTERMEDIATES AND SYNTHESIS OF QUINAGOLIDS
Disclosed is a method for preparing compounds with improved stereoselectivities. The described compounds are useful intermediates and may find particular application in the synthesis of compounds containing an octahydrobenzoquinoline moiety (e.g. an octahydrobenzo[g]quinoline moiety), such as quinagolide and its derivatives. Also disclosed is a method for stereoselectively (e.g. enantioselectively) preparing an intermediate used in the existing manufacturing process for the synthesis of quinagolide this intermediate also finding utility in the synthesis of other compounds containing an octahydrobenzo[g]quinoline moiety, in particular those having a substituent at the 3- position on the octahydrobenzo[g]quinoline.
C07C 229/34 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
C07C 227/18 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions impliquant des groupes amino ou carboxyle, p.ex. hydrolyse d'esters ou d'amides, par formation d'halogénures, de sels ou d'esters
C07C 227/32 - Préparation d'isomères optiques par synthèse stéréospécifique
A solid pharmaceutical formulation comprising a mixture of (1) lyophilized granules comprising sildenafil or a pharmaceutically acceptable salt thereof as active ingredient and (2) a non-lyophilized composition, wherein the formulation comprises 35% to 50% by weight of the lyophilized granules (1) and dissolves in the oral cavity and the non-lyophilized composition (2) is a solid blend composition comprising flow enhancing agents, a package containing the formulation, and a process for the manufacture of the formulation.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; dietetic food and substances adapted for medical use; dietary supplements for humans; medical preparations and articles Surgical and medical apparatus and instruments; parts and fittings of all the aforesaid goods included in this class Medical services; human healthcare services
Described herein are aqueous pharmaceutical compositions comprising lidocaine, hyaluronic acid, and chondroitin sulphate (or a pharmaceutically acceptable salts of any thereof) and water, as well as methods of making such aqueous pharmaceutical compositions, and therapeutic methods using them.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
17.
ENZALUTAMIDE NANOCRYSTALS, METHODS AND COMPOSITIONS
Described herein are processes for preparing enzalutamide nanocrystals, compositions and pharmaceutical compositions comprising them, and therapeutic methods using them.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres lyophilisées
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p.ex. phénytoïne
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Implant material being synthetic peptides for inducing and augmenting bone formation and repair; synthetic growth-factor peptides applied to orthopedic medical devices and materials for use with invasive and other medical procedures for inducing and augmenting bone formation and repair
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Pharmaceutical preparations; dietetic food and substances adapted for medical use; dietary supplements for humans; medical preparations.
(2) Surgical and medical apparatus and instruments. (1) Education; arranging, organizing and conducting of educational and scientific events and forums; publication of printed matter, including in electronic form (other than for advertising purposes).
(2) Medical services; human healthcare services; medical information services.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products and preparations for treating blood disorders and conditions; pharmaceutical products and preparations for treating hormonal disorders and conditions; pharmaceutical products and preparations for treating rare diseases; pharmaceutical products and preparations for treating urological disorders and conditions; pharmaceutical products and preparations for treating diabetes insipidus
This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products and preparations for the treatment of diseases and conditions in the areas of reproductive health, fertility, gynecology and obstetrics; vaginal suppositories for delivery of pharmaceuticals to the body
The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Medical research and development for others of synthetic bioactive peptides, custom compositions and coatings for medical device implants and for use in surgical procedures
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products and preparations for the prevention or treatment of urological diseases, disorders and conditions, diabetes insipidus, constipation, chronic bowel disease, arthritis, autoimmune diseases and disorders, cancer, reproductive health diseases, disorders and conditions, pain, hormonal diseases, disorders and conditions and endocrinological diseases, disorders and conditions
The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
31.
COMPOSITIONS AND METHODS FOR INTRAUTERINE INSEMINATION (IUI)
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
Methods, uses and compositions including rFSH including α2,3- and α2,6-sialylation for use in the treatment of infertility in a male patient are described.
The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
35.
Method of manufacturing a pharmaceutical composition
A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres lyophilisées
A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
A61K 31/4725 - Isoquinoléines non condensées, p.ex. papavérine contenant d'autres hétérocycles
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
Methods, uses and products including a recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation and menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age ≥35 are described.
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
39.
HP-HMG FOR USE IN THE TREATMENT OF INFERTILITY IN A PATIENT WITH POLYCYSTIC OVARY SYNDROME
Described are assisted reproductive technology compositions and methods using highly purified menotropin (HP-hMG) to stimulate follicle development, particularly in women who have been diagnosed with oligoovulation and/or PCOS and who are predicted to have a high ovarian response to controlled ovarian stimulation.
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
The invention provides a polypeptide dimer comprising two gp130-Fc fusion peptides for use in the treatment of ASCVD in human patients, preferably of high-risk ASCVD in human patients, more preferably of very-high-risk ASCVD in human patients.
C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products and preparations; gene-based
pharmaceutical products and preparations; pharmaceutical
products and preparations against cancer; pharmaceutical
products and preparations against bladder diseases; sanitary
preparations for medical purposes.
42.
COMPOSITION COMPRISING HP-HMG FOR USE IN TREATING INFERTILITY
The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stimulation.
A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
Compositions and methods for treating patients are disclosed. An example composition may include a vaginal microbiota composition. The vaginal microbiota composition may include a mixture of bacteria. The mixture of bacteria may include Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, and Lactobacillus rhamnosus.
The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.
The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical products and preparations; gene-based pharmaceutical products and preparations; pharmaceutical products and preparations against cancer; pharmaceutical products and preparations against bladder diseases; sanitary preparations for medical purposes.
Described herein are pharmaceutical compositions comprising diclofenac and therapeutic methods for using them effective with once daily administration.
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p.ex. prégnane ou progestérone
A61F 6/08 - Pessaires, c. à d. dispositifs insérés dans le vagin pour soutenir l'utérus, remédier à une malposition ou pour empêcher la conception
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
B29C 45/00 - Moulage par injection, c. à d. en forçant un volume déterminé de matière à mouler par une buse d'injection dans un moule fermé; Appareils à cet effet
A61P 5/06 - Médicaments pour le traitement des troubles du système endocrinien des hormones de l'hypophyse antérieure, p.ex. TSH, ACTH, FSH, LH, PRL, GH
A61P 5/24 - Médicaments pour le traitement des troubles du système endocrinien des hormones sexuelles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and biopharmaceutical products and preparations used for the treatment of microbiota dysfunction diseases and disorders; drug delivery devices sold filled with pharmaceutical preparations to treat gut microbiome-related disorders; drug delivery devices sold filled with pharmaceutical preparations to treat gut microbiome-related disorders in the nature of a kit comprising a prefilled suspension bag and administration tube set
A61K 47/20 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p.ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products and preparations to treat cancer and bladder diseases; gene-based pharmaceutical products and preparations to treat cancer and bladder diseases
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
Synthetic growth-factor analog peptide products, namely, peptide coated bone graft substitutes for filling voids and gaps in bone including those of the vertebral column, for use with invasive and other medical procedures
56.
ADRENOCORTICOTROPIC HORMONE PEPTIDE COMPOSITIONS AND METHODS OF USE
Described herein are aqueous pharmaceutical compositions comprising peptide Met-Glu-His-Phe-Pro-Gly-Pro (SEQ ID NO: 1), or a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt of any thereof, and therapeutic methods using them.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/18 - Amines; Amides; Urées; Composés d’ammonium quaternaire; Acides aminés; Oligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p.ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present disclosure provides methods of detection and diagnosis of ectopic endometriosis. The disclosure further provides compositions, medicaments and methods for treating or preventing ectopic endometriosis.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/473 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. acridines, phénantridines
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and biopharmaceutical products, preparations and agents for the treatment of endocrinological, urological, oncological, reproductive, fertility, gynaecological, obstetrics, gastroenterological, orthopaedics, and immunological diseases and conditions; pharmaceutical and biopharmaceutical agents for the treatment of microbiota dysfunction diseases and disorders
62.
BACTERIOPHAGES AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI
Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
63.
BACTERIOPHAGES AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI
Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Stable liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Promoting public awareness of health issues and dissemination of information promoting public awareness of health issues and healthcare; promoting public awareness of sexual health, reproductive health, fertility planning, and family planning issues and dissemination of information promoting public awareness of sexual health, reproductive health, fertility planning, and family planning issues
68.
BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
A61K 35/747 - Lactobacilles, p.ex. L. acidophilus ou L. brevis
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Escherichia coliEscherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
A61K 35/747 - Lactobacilles, p.ex. L. acidophilus ou L. brevis
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present disclosure relates to the use of a novel dosage form of merotocin in improving lactation in a female in need thereof. The disclosure particularly provides the use of a composition suitable for intranasal administration that provides a dose of merotocin greater than 100 μg or substantially about 400 μg to the female. The disclosure encompasses methods of treatment as well as compositions for use in such methods.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceutical and biopharmaceutical products and
preparations used for the treatment of diseases and
disorders emanating from microbiota dysfunction. Medical and surgical apparatus and instruments; drug
delivery devices, including medical apparatus and
instruments for administration of pharmaceutical and
biopharmaceutical products and preparations.
A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products and substances for treating orthopedic diseases and conditions; prescription peptides for treating orthopedic diseases and conditions
75.
Method of treating prostate cancer with GnRH antagonist
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Pharmaceutical and biopharmaceutical products and preparations used for the treatment of diseases and disorders emanating from microbiota dysfunction, namely, diseases and conditions in the areas of endocrinology, urology, oncology, reproductive health, fertility, gynaecology, obstetrics, gastroenterology, orthopaedics, immunology
(2) Surgical instruments; medical tubing; bags and tubing for administering gastrointestinal treatment preparations; medical devices for rectal use in administering pharmaceutical preparations for treating gastrointestinal diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and biopharmaceutical products, preparations and agents for the treatment of reproductive, fertility, gynaecological, and obstetric diseases and conditions
The present invention relates to an sgp130 protein, exemplified by olamkicept, for use 5 in treating individuals for inflammatory bowel diseases (IBD). In particular, the invention provides a panel of gene expression biomarkers that predict response in patients with inflammatory bowel disease after a single administration of as sgp130 protein, such as olamkicept.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
80.
COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
81.
COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
82.
Topical pharmaceutical composition for treatment of anal fissures and hemorrhoids
The present invention relates to a topical pharmaceutical composition to be used in the anal region for anal fissures and hemorrhoids, including the postoperative period of hemorrhoidectomy. The pharmaceutical composition comprises an anal dilator, a mucoadhesive polymer and a non-aqueous vehicle. Also described is a method of manufacturing the pharmaceutical composition.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. clothiapine, diltiazem
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
83.
Process for the preparation of drug loaded microparticles
e) allowing the spontaneous formation of the nano- and/or microparticles via transfer of organic solvent from the discontinuous organic phase into the continuous aqueous phase directly after the dispersion has been formed.
A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Promoting public awareness of health issues and healthcare Creating and hosting an on-line community for registered users to discuss health and healthcare issues, and share experiences related to health and healthcare; creating and hosting an online community to interact with registered users, and for registered users to interact with each other, through the use of animated graphics, pictures, and videos to promote awareness of health issues
The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medical and clinical research services; scientific research
for medical purposes; providing scientific information in
the field of medical disorders and their treatment;
provision of information and data relating to medical
research and development; pharmaceutical research and
development services; pharmaceutical products development;
research of pharmaceuticals; conducting clinical trials for
pharmaceutical products; information technology services for
the pharmaceutical and healthcare industries; design and
development of software for use in the medical and
pharmaceutical field; Software as a Service [SaaS] services
for use in the medical and pharmaceutical field; Platform as
a Service [PaaS] services for use in the medical and
pharmaceutical field. Human healthcare services; providing information in the
field of human health care; medical services, consultancy,
information and advisory services in the field of
pharmaceutical products and treatments; medical and health
care information services.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Drug delivery devices sold filled with pharmaceutical preparations to treat gut microbiome-related disorders; drug delivery devices sold filled with pharmaceutical preparations to treat gut microbiome-related disorders in the nature of a kit comprising a prefilled suspension bag and administration tube set
Methods for treating and/or preventing a recurrent Clostridioides difficile infection are disclosed. An example comprises administering one or more doses of an oral microbiota restoration composition to a patient with one or more episodes of a recurrent Clostridioides difficile infection. The oral microbiota restoration composition comprises a lyophilized material comprising fecal microbiota, polyethylene glycol, trehalose, sucrose, and glycerin.
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
Disclosed are methods and apparatuses for manufacturing a solid formulation for oral administration, comprising an edible substrate portion on which a composition comprising a first pharmaceutical active ingredient is deposited, and solid formulations made thereby. The methods comprise providing an edible substrate in the form of a film comprising a plurality of portions, spraying a liquid formulation comprising the active ingredient and a solvent onto an edible substrate portion and evaporating the solvent to form a solid composition deposited on the edible substrate portion; measuring the quantity of active ingredient supported by the edible substrate portion and comparing to a predetermined value, and dividing the edible substrate into the plurality of portions.
B41F 17/00 - Appareils ou machines à imprimer de type particulier ou pour emploi particulier, non prévus ailleurs
B65B 9/02 - Enserrage d'objets les uns à la suite des autres ou de quantités de matériaux, entre bandes se faisant face
B65B 35/44 - Disposition et alimentation des objets en groupes par courroies ou chaînes sans fin
B65B 57/14 - Dispositifs de commande automatique, de vérification, d'alarme ou de sécurité sensibles à l'absence, à la présence, à l'alimentation anormale ou au mauvais positionnement des objets ou matériaux à emballer et dont le fonctionnement commande ou arrête l'alimentation des objets ou matériaux à emballer
B65B 57/18 - Dispositifs de commande automatique, de vérification, d'alarme ou de sécurité déclenchant des signaux d'alarme acoustiques ou optiques
B65B 61/06 - Dispositifs accessoires, non prévus ailleurs, opérant sur feuilles, flans, bandes, attaches, réceptacles ou paquets pour découper les bandes ou pour séparer les paquets joints par coupe
97.
METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
36 - Services financiers, assurances et affaires immobilières
Produits et services
(1) Investment of funds; Providing monetary grants in the field of corporate, social responsibility, educational activities; providing monetary grants in the field of education and educational materials; providing monetary grants for events and activities, namely, scientific and professional meetings, community health fairs and health screening programs; capital investment; financial management; financial valuation of intellectual property assets; financial research services; financial investment analysis and research; financial sponsorship of medical research
Described are assisted reproductive technology compositions and methods using highly purified menotropin (HP-hMG) to stimulate follicle development, particularly in women who have been diagnosed with oligoovulation and/or PCOS and who are predicted to have a high ovarian response to controlled ovarian stimulation.
A61P 5/06 - Médicaments pour le traitement des troubles du système endocrinien des hormones de l'hypophyse antérieure, p.ex. TSH, ACTH, FSH, LH, PRL, GH
